Sanjay Keswani
Net worth: 249 263 $ as of 2026-06-29
Net worth: 249 263 $ as of 2026-06-29
Sanjay Keswani is Executive Vice Chairman at ImmunoBrain Checkpoint Ltd. since 2024.
Dr. Keswani is Director at Nura Bio, Inc. Dr. Keswani will be Chief Medical Officer at Neurocrine Biosciences, Inc. starting in 2025.
Formerly, Dr. Keswani was Chief Executive Officer at Rheos Medicines, Inc. from 2018 to 2019.
Dr. Keswani was VP-Exploratory & Clinical Translational Research at Bristol Myers Squibb Co. from 2011 to 2015.
Dr. Keswani was Senior Vice President & Global Head-Neuroscience at F.
Hoffmann-La Roche Ltd. from 2015 to 2018.
Dr. Keswani was Chief Medical Officer & Executive Vice President at Annexon, Inc. from 2019 to 2022.
Dr. Keswani was Member at The Johns Hopkins Hospital, Inc. Dr. Keswani was Assistant Professor at The Johns Hopkins University.
Dr. Keswani graduated from St Bartholomew's Hospital Medical College in 1994.
Dr. Keswani completed undergraduate studies at St Mary's Hospital Medical School in 2002.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-01 | 1,479 ( 0% ) | 249 263 $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| NEUROCRINE BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2025-06-01 |
Nura Bio, Inc.
Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops neuroprotective drugs and therapies | Director/Board Member | - |
ImmunoBrain Checkpoint Ltd.
ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company transforming the fight against neurodegeneration and aging by targeting the immune systems | Director/Board Member | - |
| Companies | Position | End |
|---|---|---|
| ANNEXON, INC. | Chief Tech/Sci/R&D Officer | 2022-02-22 |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease | Chief Executive Officer | 2019-05-31 |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 2018-08-31 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2015-05-31 |
The Johns Hopkins Hospital, Inc.
The Johns Hopkins Hospital, Inc. Hospital/Nursing ManagementHealth Services Operates as a community hospital | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 11 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Annexon, Inc.
Annexon, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for neurodegenerative and autoimmune disorders | Health Technology |
The Johns Hopkins Hospital, Inc.
The Johns Hopkins Hospital, Inc. Hospital/Nursing ManagementHealth Services Operates as a community hospital | Health Services |
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St Bartholomew's Hospital Medical College
St Bartholomew's Hospital Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St Mary's Hospital Medical School
St Mary's Hospital Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ImmunoBrain Checkpoint Ltd.
ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company transforming the fight against neurodegeneration and aging by targeting the immune systems | Health Technology |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease | Health Technology |
Nura Bio, Inc.
Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops neuroprotective drugs and therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions